‘Smaller UK public companies, typically those below £100m in size, face many barriers to accessing growth capital from the stock market. Poor liquidity results in these companies being perceived as private companies with a quote’.
02 Aug 2016
The Monthly August 2016
Allergy Therapeutics plc (AGY:LON), 3.0 | Alliance Pharma plc (APH:LON), 39.0 | City of London Investment Group PLC (CLIG:LON), 315 | Software Circle PLC (SFT:LON), 18.0 | Lombard Risk Management (LRM:LON), 0 | Murgitroyd Group (MUR:LON), 0 | PPHE Hotel Group Limited (PPH:LON), 1,405 | R.E.A. Holdings plc (RE:LON), 64.8 | Tissue Regenix Group plc (TRX:LON), 62.5 | United Cacao Ltd Sezc (CHOC:LON), 0 | Primary Health Properties PLC (PHP:LON), 93.2 | Advanced Oncotherapy Plc (AVO:LON), 1.9 | Tethys Oil AB (0A1V:LON), 4,800 | Verona Pharma plc Sponsored ADR (VRNA:NAS), 0
Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
The Monthly August 2016
Allergy Therapeutics plc (AGY:LON), 3.0 | Alliance Pharma plc (APH:LON), 39.0 | City of London Investment Group PLC (CLIG:LON), 315 | Software Circle PLC (SFT:LON), 18.0 | Lombard Risk Management (LRM:LON), 0 | Murgitroyd Group (MUR:LON), 0 | PPHE Hotel Group Limited (PPH:LON), 1,405 | R.E.A. Holdings plc (RE:LON), 64.8 | Tissue Regenix Group plc (TRX:LON), 62.5 | United Cacao Ltd Sezc (CHOC:LON), 0 | Primary Health Properties PLC (PHP:LON), 93.2 | Advanced Oncotherapy Plc (AVO:LON), 1.9 | Tethys Oil AB (0A1V:LON), 4,800 | Verona Pharma plc Sponsored ADR (VRNA:NAS), 0
- Published:
02 Aug 2016 -
Author:
Martin Hall -
Pages:
28
‘Smaller UK public companies, typically those below £100m in size, face many barriers to accessing growth capital from the stock market. Poor liquidity results in these companies being perceived as private companies with a quote’.